56 clinical trials found.
-
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-na ve EGFR-mutant Locally Advanced or Metastatic NSCLC
The purpose of this study is to find out whether the addition of ramucirumab to osimertinib is better at controlling EGFR lung cancer than just ...Phase
TRIAL ROLE: Principal Investigator
-
A Phase 1/2 Open-Label Dose-Escalation Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors
The purpose of this research study is to learn about the effects of the study drug, NC318, when given as an investigational combination treatment for ...Phase
TRIAL ROLE: Principal Investigator
-
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC) Locally Advanced or Metastatic with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
If you have been diagnosed with Non-Small Cell Lung Cancer that has tested positive for the presence of EGFR or HER2 Exon 20 Insertion (lung ...Phase
TRIAL ROLE: Principal Investigator
-
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study ...Phase
TRIAL ROLE: Principal Investigator
-
A Phase 1-2 First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Lymphomas.
The study is being done to look at: • The possible side effects, safety and tolerability of CX-2029 • The highest dose of CX-2029 that can be ...Phase
TRIAL ROLE: Principal Investigator
-
MULTICENTER PHASE II NEOADJUVANT AND ADJUVANT STUDY OF ALECTINIB ENTRECTINIB OR VEMURAFENIB PLUS COBIMETINIB IN PATIENTS WITH STAGES I-III NON-SMALL CELL LUNG CANCER WITH ALK ROS1 NTRK OR BRAF V600E MOLECULAR ALTERATIONS
The purpose of the trial is to determine the efficacy and safety of drugs in patients with untreated non-small cell lung cancer (NSCLC) tumors. In ...Phase
TRIAL ROLE: Principal Investigator
-
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer
The purpose of the study is to evaluate the safety and tolerability of BLU-945, an orally available, highly potent and selective inhibitor of EGFR resistance ...Phase
TRIAL ROLE: Principal Investigator
-
MasterKey-01: A Phase 1/2 Open-label Two-part Multicenter Study to Assess the Safety Tolerability Pharmacokinetics and Antitumor Activity of BDTX-189 an Inhibitor of Allosteric ErbB Mutations in Patients with Advanced Solid Malignancies
The purpose of the study is to determine the recommended phase two dose and dosing schedule of BDTX-189, as a single agent administered orally to ...Phase
TRIAL ROLE: Principal Investigator
-
A PHASE II OPEN-LABEL MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF NEOADJUVANT AND ADJUVANT TIRAGOLUMAB PLUS ATEZOLIZUMAB WITH OR WITHOUT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED RESECTABLE STAGE II IIIA OR SELECT IIIB NON-SMALL CELL LUNG CANCER
The purpose of the study is to determine the surgical safety and feasibility of atezolizumab plus tiragolumab alone (Atezo and Tira) or in combination with ...Phase
TRIAL ROLE: Principal Investigator
-
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb 22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)
The purpose of the study is to assess the safety and tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab. XmAb®22841 is a ...Phase
TRIAL ROLE: Principal Investigator
